PRESS RELEASE published on 05/16/2025 at 17:45, 10 months ago Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital Median Technologies discloses total voting rights and shares as of April 30, 2025, in compliance with regulations. The French company utilizes AI for cancer diagnosis and treatment Voting Rights Shares AI Median Technologies Cancer Diagnosis
BRIEF published on 03/14/2025 at 17:50, 1 year ago Median Technologies Maintains its Eligibility for the PEA-PME Scheme PEA-PME Euronext Growth Tax Benefits Eligibility Median Technologies
BRIEF published on 02/24/2025 at 17:50, 1 year ago Median Technologies: Presentation of eyonis™ LCS at ECR 2025 Artificial Intelligence Median Technologies Lung Cancer Eyonis™ LCS ECR 2025
BRIEF published on 01/31/2025 at 08:05, 1 year 1 month ago Median Technologies unveils its 2024 financial results and its 2025 outlook Financial Results FDA Approval Median Technologies Eyonis™ LCS Expansion 2025
PRESS RELEASE published on 01/31/2025 at 08:00, 1 year 1 month ago Inside Information / Other news releases Median Technologies reports 2024 financial indicators and 2025 outlook, including eyonis™ LCS FDA clearance and iCRO revenue growth. Strategic milestones and new financing agreements drive towards 2025 goals Financial Indicators Median Technologies Eyonis LCS 2025 Outlook ICRO Revenue Growth
BRIEF published on 01/24/2025 at 08:05, 1 year 1 month ago Median Technologies Secures Up to €47.5 Million for AI Lung Cancer Diagnostics European Investment Bank Median Technologies AI Lung Cancer Diagnostics Eyonis™ EU And US Commercialization
PRESS RELEASE published on 01/24/2025 at 08:00, 1 year 1 month ago Inside Information / Other news releases Median Technologies secures up to €47.5 million for eyonis™ AI lung cancer diagnostic regulatory filings & U.S./EU commercialization. New financing & operational enhancements drive profitability & extend cash runway into Q4, 2025 AI Commercialization Median Technologies Lung Cancer Diagnostic Eyonis
BRIEF published on 11/26/2024 at 17:50, 1 year 3 months ago Median Technologies Showcases AI Lung Cancer Diagnostic at RSNA 2024 Clinical Trials Eyonis™ LCS RSNA 2024 AI-powered Diagnostics Lung Cancer Screening
PRESS RELEASE published on 11/26/2024 at 17:45, 1 year 3 months ago Inside Information / Other news releases Median Technologies to showcase AI-powered lung cancer diagnostic eyonis™ LCS at RSNA 2024. Company presents latest developments and REALITY study results to experts in medical imaging conference AI-powered Median Technologies Eyonis LCS RSNA 2024 Lung Cancer Diagnostic
BRIEF published on 10/30/2024 at 17:50, 1 year 4 months ago Median Technologies and AI in lung cancer screening Artificial Intelligence Medical Technologies Lung Cancer Webconférence 2024 Medical Screening
Published on 03/16/2026 at 22:30, 8 hours 49 minutes ago Core Silver Intersects High-Grade Copper-Molybdenum Veins up to 7.31% Cu & 1.01% Mo Confirming Large Porphyry System at Laverdiere
Published on 03/16/2026 at 22:00, 9 hours 19 minutes ago Viemed Healthcare to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19
Published on 03/16/2026 at 21:30, 9 hours 49 minutes ago Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million in Liquidity
Published on 03/16/2026 at 21:00, 10 hours 19 minutes ago Amdocs Brings AI-Accelerated Application Modernization to Enterprises with NVIDIA
Published on 03/17/2026 at 07:05, 13 minutes ago Sequential™ Raises $3.5M to Build AI-Powered Discovery Platform for Multi-Omic Testing and Next-Generation Skin Health Ingredients
Published on 03/17/2026 at 07:03, 16 minutes ago Sartorius Stedim Biotech sharpens strategy with biopharma focus and sets new mid-term growth targets
Published on 03/17/2026 at 07:00, 19 minutes ago PolyPeptide publishes invitation to the annual General Meeting 2026
Published on 03/17/2026 at 07:00, 19 minutes ago Very strong business performance delivered in 2025. Continued growth expected in 2026
Published on 03/17/2026 at 06:59, 19 minutes ago Sartorius sharpens strategy with biopharma focus and sets new mid-term growth targets
Published on 03/17/2026 at 07:00, 19 minutes ago Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 13 hours 19 minutes ago Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 13 hours 21 minutes ago Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 13 hours 22 minutes ago Reporting on share buyback transactions carried out between March 9 and March 13, 2026
